Stock ELUT ELUTIA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Elutia Inc.

Equities

ELUT

US05479K1060

Market Closed - Nasdaq
Other stock markets
 02:00:01 15/05/2024 am IST 		5-day change 1st Jan Change
3.34 USD -2.34% Intraday chart for Elutia Inc. +15.17% +54.63%
09/05 Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
09/05 Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M
MT
Elutia Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Elutia Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (ELUT) ELUTIA Posts Q4 Revenue $5.9M, vs. Street Est of $6.6M
MT
Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance
CI
Elutia Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (ELUT) ELUTIA Reports Q3 Revenue $6.1M, vs. Street Est of $7.3M
MT
Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. for $34.6 million.
CI
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business
MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms
DJ
Elutia Sells Orthobiologics Business Unit For Up to $35 Million
MT
Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. for $35 million.
CI
Aziyo Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (AZYO) AZIYO BIOLOGICS Posts Q2 Revenue $10.3M, vs. Street Est of $12.5M
MT
Aziyo Biologics Voluntarily Recalls Bone-Repair Products
MT
Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products
CI
Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope
CI
Aziyo Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo's Cardiovascular Portfolio
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELUT Stock
  4. News Elutia Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW